Characterization of Pre-Existing Immunity to AAV5

被引：0
|
作者：
Lau, Kelly [1 ]
机构：
[1] BioMarin Pharmaceut Inc, Novato, CA USA
来源：
MOLECULAR THERAPY | 2023年 / 31卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
1074
引用
收藏
页码：515 / 515
页数：1
相关论文
共 50 条
  • [41] Pre-Existing Adaptive Immunity to Cas9 Proteins
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (04) : 782 - 782
  • [42] Exploiting host pre-existing immunity for melanoma cancer immunotherapy
    Briquez, Priscilla S.
    Hauert, Sylvie
    Repond, Gregoire
    Swartz, Melody A.
    Hubbell, Jeffrey A.
    CANCER RESEARCH, 2019, 79 (13)
  • [43] Impact of Pre-Existing Immunogenicity to AAV on Vector Transduction By Bmn 270, an AAV5-Based Gene Therapy Treatment for Hemophilia A
    Long, Brian
    Sandza, Krystal
    Holcomb, Jennifer
    Pherarolis, Juli
    Crockett, Lucy
    Falese, Lillian
    Hayes, Greg
    Arens, Jeremy
    O'Neill, Charles A.
    Pryer, Nancy
    Fonck, Carlos
    Zoog, Stephen
    Vettermann, Christian
    BLOOD, 2017, 130
  • [44] Characterization of Lung Eosinophil Subsets During Respiratory Viral Infection in Mice with Pre-Existing Immunity
    Chang, Lauren A.
    Choi, Angela
    Rathnasinghe, Raveen
    Warang, Prajakta
    Noureddine, Moataz
    Jangra, Sonia
    Garcia-Sastre, Adolfo
    Schotsaert, Michael
    JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [45] Intracellular Trafficking of AAV5 Vectors
    Balakrishnan, Balaji
    Jayandharan, Giridhara R.
    HUMAN GENE THERAPY METHODS, 2016, 27 (02) : 47 - 48
  • [46] Development of a Peptide ELISA for the Screening of Pre-Existing Anti-AAV Antibodies
    Daniel, Hubert
    Agbandje-Mckenna, Mavis
    Gabriel, Nishanth
    Kumar, Sanjay
    Coleman, Kirsten
    Srivastava, Arun
    Kannangai, Rajesh
    Abraham, Asha M.
    Srivastava, Alok
    MOLECULAR THERAPY, 2019, 27 (04) : 218 - 218
  • [47] Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques
    Greig, Jenny A.
    Calcedo, Roberto
    Grant, Rebecca L.
    Peng, Hui
    Medina-Jaszek, C. Angelica
    Ahonkhai, Omua
    Qin, Qiuyue
    Roy, Soumitra
    Tretiakova, Anna P.
    Wilson, James M.
    VACCINE, 2016, 34 (50) : 6323 - 6329
  • [48] Sensitivity of Different AAV Serotypes to Pre-Existing Human Nabs, In Vivo Impact
    Ros, Irene
    Salas, David
    Rodriguez, Estefania
    Ferrer, Veronica
    Douar, Anne
    Philippe Combal, Jean
    Hommel, Mirja
    Gonzalez-Aseguinolaza, Gloria
    MOLECULAR THERAPY, 2020, 28 (04) : 181 - 182
  • [49] . Therapeutic Factor IX (FIX) Activity after Single Treatment with AMT-060 (AAV5-FIX) in Hemophilia B Patients with Pre-Existing Anti-AAV5 Humoral Immunity
    Majowicz, Anna
    Nijmeijer, Bart
    Lampen, Margit H.
    Spronck, Lisa
    de Haan, Martin
    Petry, Harald
    van Deventer, Sander
    Meyer, Christian
    Tangelder, Marco
    Ferreira, Valerie
    MOLECULAR THERAPY, 2018, 26 (05) : 458 - 458
  • [50] The prevalence of pre-existing humoral immunity to AAV in adults with severe haemophilia: interim results from an ongoing global epidemiology study
    Rajavel, K.
    Chapin, J.
    Monahan, P.
    Tang, Y.
    HUMAN GENE THERAPY, 2018, 29 (12) : A41 - A41
12345